iTAg Tetramer/APC - HLA-A*02:01 HTLV-1 (LLFGYPVYV)

MBL Life Sciences

Catalog No.:
MBL-TS-M017-2
iTAg Tetramer/APC - HLA-A*02:01 HTLV-1 (LLFGYPVYV)
Shipping:
Calculated at Checkout
$1,613.00
Formerly Catalog No.: TB-M017-2
Adding to cart… The item has been added

Related Products

The α3 mutation significantly reduces the binding of MHC tetramer to human CD8. To minimizes the aberrant effect of some CD8 antibodies; clone SFCI21Thy2D3 (also known as “T8”) is recommended.

Product Specifications
Application FC
Reactivity Human
Conjugation APC
Immunogen HTLV-1
Peptide Sequence LLFGYPVYV
Class Class I
Sequence Location 11-19
MHC Allele A*02:01

Documents & Links for iTAg Tetramer/APC - HLA-A*02:01 HTLV-1 (LLFGYPVYV)
Datasheet iTAg Tetramer/APC - HLA-A*02:01 HTLV-1 (LLFGYPVYV) Datasheet

Documents & Links for iTAg Tetramer/APC - HLA-A*02:01 HTLV-1 (LLFGYPVYV)
Datasheet iTAg Tetramer/APC - HLA-A*02:01 HTLV-1 (LLFGYPVYV) Datasheet
Citations for iTAg Tetramer/APC - HLA-A*02:01 HTLV-1 (LLFGYPVYV) – 1 Found
Kozako, Tomohiro; Yoshimitsu, Makoto; Akimoto, Masaki; White, Yohann; Matsushita, Kakushi; Soeda, Shinji; Shimeno, Hiroshi; Kubota, Ryuji; Izumo, Shuji; Arima, Naomichi. Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders. Human Immunology. 2011;72(11):1001-6.  PubMed
!